key: cord-0876235-tdeoiby2
authors: Sechi, A.; Pierobon, E.; Pezzolo, E.; Germi, L.; Trevisan, G.; Zardo, D.; Riva, G.; Mondino, S.; Naldi, L.
title: Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID‐19 vaccine
date: 2021-10-21
journal: Clin Exp Dermatol
DOI: 10.1111/ced.14970
sha: 15d214b88d49edd354c526904e226b6163c4453a
doc_id: 876235
cord_uid: tdeoiby2

Developing and manufacturing effective vaccines against Coronavirus Disease 2019 (COVID-19) have been epic achievements in record time. We believe that the vaccine will help stop the pandemic due to the SARS-CoV-2 virus. As for other medical interventions, vaccines may carry a small risk of adverse reactions, especially when used on large populations outside the highly controlled phase 3 clinical trials setting. We herein report five cases of heterogeneous rare, severe cutaneous conditions arising in close connection with Covid-19 vaccination (Table 1).

northeast Italy) had been vaccinated, with a male : female ratio of 3 : 2. The priority was accorded to older people (> 80 years), healthcare workers and school staff. Overall, 187 adverse events were recorded. Besides the more common reactions reflecting aspecific activation of the immune system such as urticaria and cutaneous rash, we observed four rare acute conditions in five recently vaccinated patients [pityriasis rubra pilaris (PRP) in two patients, and Sweet syndrome (SS), pityriasis lichenoides et varioliformis acuta (PLEVA) and erythema multiforme (EM) in one patient each] (Fig. 1 ). All these conditions were confirmed histologically ( Fig. 2) and appeared within the first 2 weeks following the first dose of the COVID-19 vaccine.

To better characterize the relationship between these possible ARs and vaccine administration, we used the Naranjo Adverse Drug Reaction Probability Scale, 1 obtaining a score for each patient indicating a 'probable' causality link ( Table 2) . All patients had undergone a COVID-19 throat swab test 2 weeks prior to the vaccine, which was negative, and none of them had been infected since the pandemic started. None of the patients had any medical history of previous ARs to drugs or vaccines, or of any dermatological disorders.

A number of cutaneous conditions following COVID-19 immunization have been reported, most of which were mild and self-limiting such as local injection-site There is a debate about the capacity of COVID-19 vaccines to trigger immune-mediated conditions, either with exacerbation of pre-existing or new onset of immunemediated disorders. These events may result from upregulated inflammatory immunological pathways or crossreactivity between viral or adjuvant molecules and self-antigens. Other vaccines have been associated with immune-mediated cutaneous ARs, including EM, cutaneous lupus, Gianotti-Crosti syndrome, lichenoid eruption and granuloma annulare, 4 and also a few cases of SS, PRP and PLEVA. 5 The causal relationship between mRNA vaccines and cutaneous immunological reactions is still under debate, and we cannot exclude that the events we have reported were purely coincidental. Systemic surveillance and accurate reporting are essential to estimate associations and better qualify the potentially at-risk population, defining effective management strategies. 

A method for estimating the probability of adverse drug reactions

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases

Sweet syndrome induced by SARS-CoV2 Pfizer-BioNTech mRNA vaccine

Immune-mediated adverse reactions to vaccines

Pityriasis lichenoides et varioliformis acuta: a rare association with the measles, mumps and rubella vaccine